ADMP - Adamis Pharmaceuticals Corporation
| Previous Close | 0.5400 |
| Open | 0.5491 |
| Bid | 0.5101 x 3000 |
| Ask | 0.5240 x 800 |
| Day's Range | 0.5000 - 0.5491 |
| 52 Week Range | 0.4900 - 3.2900 |
| Volume | 322,401 |
| Avg. Volume | 787,323 |
| Market Cap | 31.677M |
| Beta (3Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8310 |
| Earnings Date | Nov 7, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.37 |
- GlobeNewswire
Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
Adamis Pharmaceuticals Corporation (ADMP) (“Adamis”) announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology (IHV) meeting (http://www.ihv.org/ihvmeeting/Program/) in a session on “Opioid Intersection”. Other participants at the meeting included Dr. Robert Gallo, Co-Founder and Director, Institute of Human Virology, Dr. Nora Volkow, Director, National Institute of Drug Abuse, National Institutes of Health, and Admiral Brett Giroir, MD, Assistant Secretary for Health, US Department of Health and Human Services. Naloxone is an opioid antagonist that competes opioids off their receptors in the brain.
- GlobeNewswire
Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand
Adamis Pharmaceuticals Corporation (ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ SYMJEPI® (epinephrine) Injection products in Australia and New Zealand.
- GlobeNewswire
Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting
Adamis Pharmaceuticals Corporation (ADMP) announced today that Dr. Ronald Moss, Chief Medical Officer, will be presenting data on October 4, 2019, pertaining to the company’s investigational high dose naloxone product candidate (ZIMHI) at the Institute of Human Virology (IHV) meeting (http://www.ihv.org/ihvmeeting/Program/) in a session on “Opioid Intersection”. Other participants at the meeting will be public health experts including Dr. Robert Gallo, Co-Founder and Director, Institute of Human Virology, Dr. Robert Redfield, Director of the Centers for Disease Control and Prevention (CDC), and Dr. Nora Volkow, Director, National Institute of Drug Abuse, National Institutes of Health. Naloxone is an opioid antagonist that competes opioids off their receptors in the brain.
- Simply Wall St.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): What Does Its Beta Value Mean For Your Portfolio?
If you own shares in Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) then it's worth thinking about how it...
- GlobeNewswire
Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
In June, the Company amended the New Drug Application (NDA) for ZIMHI to remove any reference to EVZIO® and withdrew the Paragraph IV certification relating to that product. On August 8, the Company announced it was conducting additional PK studies comparing ZIMHI and a relevant comparator. The data for the PK study has been recorded and is complete. The data base will be forwarded to the FDA this month. As previously announced, the PDUFA date remains October 31, 2019.
- GlobeNewswire
Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI
Adamis Pharmaceuticals Corporation (ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPITM (epinephrine) 0.3 mg and 0.15 mg Injections. During this back-to-school season, there is a heightened awareness of the shortage for epinephrine auto injectors. Adamis, in collaboration with Sandoz, Inc., hopes to alleviate some of the demand with their recently launched both doses of SYMJEPI into the hospital and retail market.
- GlobeNewswire
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
SAN DIEGO, Aug. 26, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors..
- Thomson Reuters StreetEvents
Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 Adamis Pharmaceuticals Corp Earnings Call
- GlobeNewswire
Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
Ulcers are common in the majority of horses that are subject to stress and can affect horses at any age. Examples of horses under stress include racehorses, endurance horses, dressage horses, hunters, jumpers, 3-day eventers and any type of rodeo horse. In general, horses that are in active training tend to have a prevalence of ulcers in the range of 90 to 95%. Historically, ulcers have been known to negatively affect feeding habits and performance on the track.
- Zacks
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
Adamis (ADMP) delivered earnings and revenue surprises of -33.33% and -1.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
SAN DIEGO, Aug. 08, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a.
- Simply Wall St.
Did Changing Sentiment Drive Adamis Pharmaceuticals's (NASDAQ:ADMP) Share Price Down A Painful 73%?
Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply accept every...
- GlobeNewswire
Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO, Aug. 05, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and.
- Zacks
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today the pricing of its previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase up to 12,000,000 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined public offering price of $1.00, resulting in gross proceeds of approximately $12,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company and excluding the proceeds from the exercise of any warrants.
- GlobeNewswire
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today that it intends to offer to sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants to purchase shares of its common stock offered in the public offering.
- Zacks
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.
- Zacks
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
Masimo's (MASI) recent developments likely to show on second-quarter results.
- Zacks
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the United States District Court for the Middle District of Florida in which Adamis was seeking a declaratory judgment of non-infringement of certain patents in which Belcher claimed rights, relating to certain methods of preparing epinephrine solutions (“Patent Case”), and the inter partes review proceeding filed by Adamis in the United States Patent and Trademark Office requesting a formal review the validity of certain aspect of Belcher’s patents (“IPR”).
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company’s SYMJEPI™ (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products are FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis is developing additional products, including the company’s ZIMHI™ naloxone injection product candidate for the treatment of opioid overdose, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs and certain nonsterile drugs for human and veterinary use, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
SAN DIEGO, July 09, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail.
- Reuters
Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen. The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner. Mylan dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.
- Simply Wall St.
Have Insiders Been Selling Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
